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Abstract
Background: Many novel vaccines can cover only a fraction of all antigenic types of a pathogen. Vaccine effectiveness (VE)
in the presence of interactions between vaccine strains and others is complicated by the interacting transmission dynamics
among all strains. The present study investigated how the VE estimates measured in the field, based on estimated odds
ratio or relative risks, are scaled by vaccination coverage and the transmission dynamics in the presence of cross-protective
immunity between two strains, i.e. vaccine and non-vaccine strains.
Methodology/Principal Findings: Two different types of epidemiological models, i.e. with and without re-infection by the
same antigenic type, were investigated. We computed the relative risk of infection and the odds ratio of vaccination, the
latter of which has been measured by indirect cohort method as applied to vaccine effectiveness study of Streptococcus
pneumoniae. The VE based on the relative risk was less sensitive to epidemiological dynamics such as cross-protective
immunity and vaccination coverage than the VE calculated from the odds ratio, and this was especially the case for the
model without re-infection. Vaccine-induced (cross-protective) immunity against a non-vaccine strain appeared to yield the
highest impact on the VE estimate calculated from the odds ratio of vaccination.
Conclusion: It is essential to understand the transmission dynamics of non-vaccine strains so that epidemiological methods
can appropriately measure both the direct and indirect population impact of vaccination. For pathogens with interacting
antigenic types, the most valid estimates of VE, that are unlikely to be biased by the transmission dynamics, may be
obtained from longitudinal prospective studies that permit estimation of the VE based on the relative risk of infection
among vaccinated compared to unvaccinated individuals.
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Introduction
Since new vaccines are continuously developed and introduced
to human population, it is essential to assess how effective the
vaccination is both at the individual and population levels.
Conventionally, vaccine efficacy at an individual level has been
measured as the relative reduction in the conditional risk of
infection (given an exposure) among vaccinated individuals as
compared to unvaccinated, most typically, through randomized
controlled trials. To make a clear distinction in the present study,
hereafter the vaccine effectiveness (VE) is defined as the relative
reduction of the risk of infection among vaccinated population to
that among unvaccinated population at a population level,
reflecting herd immunity and other properties of the transmission
dynamics [1]. Since the latter measure, i.e., the risk at the
population level, involves an observational problem that stems
from dependence in the risk of infection between individuals in the
same population, epidemiological studies of vaccination have
required us to consider various types of study designs and statistical
methods [2]. Moreover, due to the dependence in the risk of
infection, vaccine effectiveness at the population level is likely to
differ from vaccine efficacy at an individual level, and thus, it has
been shown that the vaccine effectiveness is influenced not only by
the efficacy but also by vaccination coverage, contact patterns,
diagnostic performance and other factors that govern the
transmission dynamics of infectious diseases [3]. The pressing
public health question of identifying such epidemiological deter-
minants of vaccine effectiveness and corresponding selection of
appropriate study designs have been addressed by employing
epidemiological modeling techniques [1,4].
However, two critical aspects of vaccination have yet to be
explored. First, published epidemiological studies that linked
efficacy with effectiveness by employing mathematical models
have tended to focus on an epidemic setting [1], while in reality a
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newly introduced vaccine tends to target an existing endemic
disease. Rather than an epidemic model that does not account for
underlying demographic dynamics in the human population, one
has to consider epidemiological dynamics on a longer time scale.
Second, many recent vaccines are designed to prevent infection
with a pathogen that consists of multiple antigenic types, and thus,
it can be important to explicitly model the epidemiological
dynamics of two or more interacting strains to capture the
underlying epidemiological mechanisms.
When it comes to multiple antigenic types, it should be noted
that many diseases are caused by antigenically diverse pathogens,
and more importantly, many new vaccines can only protect
against infection with particular antigenic types. In such an
instance, epidemiology of vaccination against a multi-strain disease
involves not only the issue of limited clinical protection from a
limited number of strains but also a complex epidemiological
problem in scaling vaccine effectiveness by vaccination coverage
and the transmission dynamics. In the absence of vaccination,
susceptibility to a certain strain is determined not only by the
exposure to the same strain, but also by exposure to other strains
that offer cross-protective immunity against the strain of interest.
In that case, vaccination can not only directly reduce the risk of
infection with vaccine strain(s) but also indirectly vary the risk of
infection by varying cross-protective immunity that is induced by
infection with other strains. Thus, the effectiveness of vaccination
in the presence of cross-protective immunity between vaccine
strains and others is characterized by complex interactions among
all strains [5,6,7,8].
The present study aims to clarify how the epidemiologically
observed risk measures, which are used to inform vaccine
effectiveness, in the presence of interacting antigenic types, are
scaled by vaccination coverage and the transmission dynamics.
Employing simple epidemiological models that are suited to
consider an endemic situation, we identify key epidemiological
determinants that influence the vaccine effectiveness and discuss
the current data gaps that need to be addressed to appropriately
assess the effectiveness of vaccination.
Materials and Methods
Diseases with and without Re-infection
Hereafter, we refer to antigenic types that are covered by
vaccination as vaccine type (VT) and others as non-vaccine types
(NVT). For simplicity, the present study considers a situation in
which there are only two strains, i.e., VT and NVT. For the
exposition of our model-based arguments, we consider two
diseases with multiple antigenic types. One is hand-foot-and-
mouth disease (HFMD), especially that caused by enterovirus 71
(EV71). It has been demonstrated that EV71 involves genogroups
with cross-antigenicity in the experimental setting [9], while a
vaccine under development may only partially protect vaccinated
individuals from certain antigenic type(s) [10]. In this setting, we
assume that infection with a single strain (either VT or NVT)
elicits life-long immunity, and thus, we model the epidemiological
dynamics by employing the SIR (Susceptible-Infectious-Recov-
ered) model with two strains, but without re-infection (Figure 1).
Another disease to be considered is the infection, carriage and
colonization with Streptococcus pneumoniae (pneumococcus) which
involves more than 90 serotypes, while currently available vaccines
have covered only a certain number of serotypes (e.g. PCV7 that
offers protection from 7 serotypes) [11]. As is also the case for
EV71, a relative reduction in the risk of carriage acquisition has
been demonstrated for pneumococcus by competition between
VT and NVT, and the replacement of major serotypes has been
observed after introducing PCV7 into a new community [12]. It is
known that the natural remittance occurs, and carriages due to
recurrent exposures with the same serotype have also been
observed [13]. Thus, we use the SIS (Susceptible-Infected-
Susceptible) model that allows multiple re-infections (Figure 1).
Vaccine Effectiveness
Vaccine effectiveness (VE) is calculated as the relative risk
reduction among the vaccinated population as compared with the
unvaccinated population [3]. The relative risk (RR) of infection or
its approximation can be measured from epidemiological studies.
In retrospective studies, the odds ratio (OR) of infection has been
employed as an approximation to RR. The OR is often used due
to the epidemiological and clinical characteristics of a disease (e.g.
a clinically non-apparent disease with low prevalence).
As another type of OR for the estimation of vaccine
effectiveness, an indirect cohort method, or the so-called Broome
method, has been applied to pneumococcus [14,15,16], in which
the OR of ‘‘vaccination’’ among VT cases to NVT cases with IPD
(invasive pneumococcal disease) has been used for the assessment
of vaccine effectiveness. This method has been proposed because
the exposure with pneumococcus tends to result in clinically very
mild infection or carriage, and perhaps also because the method
requires us to collect only the counts of IPD cases with strain
information (i.e. VT or NVT) and their vaccination histories [14].
Although the Broome method has been positively assessed
elsewhere [11], the validity has yet to be explicitly assessed by
accounting for detailed interactions between VT and NVT in a
mathematically rigorous manner, because the method inherently
assumes that there is no interference between VT and NVT. To
examine how vaccine effectiveness is scaled by the coverage, cross-
protective immunity and other epidemiological features, we
computed the vaccine effectiveness using two different epidemi-
ological measures, using mathematical models with an assumed
vaccine efficacy. Vaccine effectiveness calculated from the relative
risk of infection, VER and from the odds ratio of vaccination, VEO
are written as
VER~1{RRVT ,
VEO~1{ORVT ,
ð1Þ
where RRVT is the relative risk of infection with VT among
vaccinated individuals as compared with unvaccinated, and ORVT
is the odds ratio of vaccination among IPD cases with VT to IPD
cases with NVT.
Mathematical Model
Figure 1 shows the structures of the SIR and SIS type models.
In the case of SIR (i.e. model for EV71), we assume that serotype-
specific life-long immunity is acquired from infection with either
VT or NVT which also yields a cross-protective immunity against
infection with the other serotype. Cross-protective immunity is
similarly considered in the SIS model (i.e. model for pneumococ-
cus), and this model permits re-infections with the same serotype.
We consider two different types of immunity for both naturally
acquired and vaccine-induced ones, (i) all-or-nothing type which
elicits a perfect protection from infection with probability s, and
(ii) leaky type immunity which reduces the conditional probability
of infection given an exposure by the factor of relative reduction s.
When we adopt either of the two types for vaccine-induced
immunity, the naturally acquired immunity is also assumed to
follow the same type of immunity. For both models, the
background birth and death rates of human host are assumed as
Vaccine Effectiveness and Cross Immunity
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identical, m. The mathematical descriptions of these models are
given in the Appendix. As a general representation of the two
models, we also explore the so-called SIRS (susceptible-infectious-
recovered-susceptible) model in the Online Supporting Material.
To assess VE, we use endemic steady state solution of the
models in the presence of vaccination. As for the epidemiological
actions of different types of vaccine, all-or-nothing vaccine is
assumed to provide vaccinated individuals with perfect protection
against VT (or NVT) with a probability eVT (or eNVT), and the
remaining proportion of vaccinated individuals remain susceptible.
Leaky vaccine reduces the instantaneous risk of infection upon
each exposure to VT (or NVT) by the factor of reduction eVT (or
eNVT). We specifically consider the two types of vaccine, because
the actual biological action of both vaccines is unknown.
All-or-nothing vaccine. Analyzing the SIR model in an
endemic steady state, vaccine effectiveness against VT, given
vaccine efficacy against VT, eVT, using the relative risk of infection
is calculated as
VER~1{RRVT
~1{(1{eVT )bA,AOR,
ð2Þ
where, as described in the Supporting Information, bA,AOR adjusts
the interaction between VT and NVT and herd immunity, i.e.,
bA,AOR~1z
eNVT
Thoseprotected from VT by cross-protective immunity
Thoseunprotected from VT
,
ð3Þ
where eNVT is the vaccine efficacy against NVT. Here ‘‘those
protected from VT by cross-protective immunity’’ represents the
population fraction of individuals who escape from infection with
Figure 1. Transmission dynamics of two-strain disease in the presence of cross-protective immunity. (a) Model without re-infection with
an identical antigenic type (SIR-type; susceptible-infectious-recovered) and (b) model with re-infections by an identical antigenic type (SIS-type;
susceptible-infected-susceptible). SIR model is intended to capture the epidemiological dynamics of EV71, while SIS model is applied to
pneumococcus. [Compartments] Variable u represents unvaccinated. Two subscripts represent the state of infection (or carriage) with respect to VT
and NVT, respectively. For example, usi represents unvaccinated host who is susceptible to VT but is infected with NVT. [Parameters] c, vaccination
coverage; m, background birth and death rates of human host; lA and lB, the rates of infection with VT (vaccine type) and NVT (non-vaccine type),
respectively; cA and cB, recovery rates from infection with VT and NVT, respectively; s, the relative reduction of the risk of infection upon exposure by
cross-protective immunity in the SIR model; sA and sB, the relative reduction of the risk of carriage acquisition upon exposure to VT and NVT by
competition, respectively, in the SIS model. For simplicity, both panels represent the population dynamics of unvaccinated population alone. In case
no vaccination takes place, c is equal to 0.
doi:10.1371/journal.pone.0050751.g001
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VT due to cross-protective immunity (or the frequency of those
escaping from carriage acquisition of VT due to competition
between VT and NVT). The mathematical representation of these
terms and the derivation are given in the Supporting Information.
Using odds ratio of vaccination, VEO is
VEO~1{ORVT
~1{
(1{eVT )bA,AOR
(1{eNVT )bB,AOR
,
ð4Þ
where, again as described in the Supporting Information, bB,AOR
adjusts the interaction between NVT and VT and the transmission
dynamics, as in a similar fashion to bA,AOR and reads
bB,AOR~1z
eVT
Those protected from NVT by cross-protective immunity
Those unprotected population from NVT
:
ð5Þ
In the absence of cross-protective immunity as well as vaccine-
induced protection against NVT, VER is equal to an unbiased
vaccine efficacy against VT, eVT. Since equation (3) is always 1 or
greater, VER tends to be an underestimate of eVT. Moreover, if
additionally there is no cross-protective immunity between VT
and NVT and if vaccine efficacy against NVT is zero, VEO is
equal to both VER and eVT.
Leaky vaccine. At an endemic steady state of SIR model,
vaccine effectiveness against VT is calculated using the relative risk
of infection:
VER~1{RRVT
~1{(1{eVT )bA,Leaky,
ð6Þ
where eVT is the unbiased vaccine efficacy against VT. bA,Leaky
scales the impact of interaction and herd immunity on the
epidemiological dynamics:
bA,Leaky~
1{c
c
|
at risk of VT among vaccinated
at risk of VT among unvaccinated
, ð7Þ
where c denotes the effective vaccination coverage (i.e. the fraction
of vaccinated and protected fraction). VEO is written as
Table 1. Parameter values for the SIR (Susceptible-Infectious-Recovered) model as applied to the epidemiological dynamics of
enterovirus 71.
Symbol Description Baseline value
Plausible range in
published studies References
s Cross-protective immunity 0.5 Assumed
eVT Vaccine efficacy against VT 0.6–0.8 Assumed
eNVT Vaccine efficacy against NVT 0.3 Assumed
R0,VT The basic reproduction number of VT 4.0 1.4–6.5 [18,19]
R0,NVT The basic reproduction number of NVT 4.0 1.4–6.5 [18,19]
1/cA Infectious period of VT (days) 7 3–14 [18,19]
1/cB Infectious period of NVT (days) 7 3–14 [18,19]
doi:10.1371/journal.pone.0050751.t001
Table 2. Parameter values for the SIS (Susceptible-Infected-Susceptible) as applied to the epidemiological dynamics of
Streptococcus pneumoniae.
Symbol Description Baseline value
Plausible range in
published studies References
sA Relative reduction in carriage acquisition
of VT by competition
0.1 0.0–0.5 [13]
sB Relative reduction in carriage acquisition
of NVT by competition
0.4 0.0–1.0 [13]
eVT Vaccine efficacy against carriage acquisition of VT 0.6 0.1–0.9 [28] and assumed
eNVT Vaccine efficacy against carriage acquisition of NVT 0.1 Assumed
eVTi Vaccine efficacy against invasion of VT 0.7 0.7–1.0 [13,29]
eNVTi Vaccine efficacy against invasion of NVT 0.1 Assumed
R0,VT The basic reproduction number of VT 1.3 0.9–1.4 [13]
R0,NVT The basic reproduction number of NVT 1.2 1.0–1.6 [13]
1/cA Infectious period of VT (days) 70 40–120 [13]
1/cB Infectious period of NVT (days) 50 40–120 [13]
doi:10.1371/journal.pone.0050751.t002
Vaccine Effectiveness and Cross Immunity
PLOS ONE | www.plosone.org 4 November 2012 | Volume 7 | Issue 11 | e50751
Vaccine Effectiveness and Cross Immunity
PLOS ONE | www.plosone.org 5 November 2012 | Volume 7 | Issue 11 | e50751
VEO~1{
RRVT
RRNVT
~1{
1{eVT
1{eNVT
|
bA,Leaky
bB,Leaky
,
ð8Þ
where bB,Leaky is
bB,Leaky~
1{c
c
|
at risk of NVT among vaccinated
at risk of NVT among unvaccinated
: ð9Þ
From equations (6) and (7), VER is equal to eVT if the frequency of
those at risk of VT among vaccinated is equal to the frequency of
those at risk of VT among unvaccinated. Unlike all-or-nothing
vaccine, VER is unequal to eVT even when there is no cross-
protective immunity, because the size of the at risk population
depends on vaccination coverage and vaccine efficacy eVT. In the
absence of cross-protective immunity and given that vaccine
efficacy against NVT is zero, VEO is equal to VER. The
arguments similar to equations (2)-(9) can also hold for the SIS
model (see Supporting Information).
Only for pneumococcus, it should be noted that we assess the
vaccine effectiveness by the reduced incidence of IPD cases. We
separate the efficacy of pneumococcal vaccine into two parts, i.e.
the efficacy against becoming a carriage of VT, eVT, and
conditional protection from IPD given infectious exposure, eVTi.
The unconditional vaccine efficacy against IPD caused by VT and
NVT, e1 and e2, is written as
e1~1{(1{eVT )(1{eVTi),
e2~1{(1{eNVT )(1{eNVTi),
ð10Þ
where eNVT and eNVTi are the efficacy against NVT and
conditional protection from IPD given an infectious exposure,
respectively.
Heterogeneity. Although the above mentioned descriptions
rest on the assumption of homogeneous mixing between vacci-
nated and unvaccinated individuals, it may be more realistic to
consider heterogeneous contact patterns, e.g. more frequent
contact within the unvaccinated subpopulation. To describe
within- and between-group transmission in a population that
consists of vaccinated and unvaccinated individuals, we employ
the so-called preferred mixing assumption [17]. The transmission
coefficient of serotype h (VT or NVT) that a primary case in
subpopulation i transmits to susceptibles in subpopulation j, bhij is
proportional to
bhij!
1{h i=j,
h
nj
z1{h i~j,
(
ð11Þ
where nj represents the relative population size of subpopulation j
and h is the assortativity coefficient, i.e., the proportion of contacts
that are spent for within-subpopulation mixing. As the sensitivity
analysis, we vary h from 0–0.3 and examine the sensitivity of
vaccine effectiveness to h.
Tables 1 and 2 show parameter values and ranges that we
examine in numerical analysis. The sensitivity of VER and VEO to
different vaccine efficacies against VT and NVT, vaccination
coverage, the strength of cross-protective immunity against VT
and NVT are examined. The basic reproduction numbers of VT
and NVT are derived from the linearlized system nearby disease-
free equilibrium in the absence of the other serotype and without
vaccination. Based on published estimates, R0 for EV71 are
assumed to be 4.0 with the range from 1.4 to 6.5 for both VT and
NVT [18,19]. As for pneumococcus, R0 is estimated from
longitudinal observation of incidence and remission [13] and are
assumed to be 1.3 (range 0.9–1.4) and 1.2 (1.0–1.6) for VT and
NVT, respectively. Regarding the vaccination coverage, c, we
assume c=0.5 for EV71 and c=0.2 for pneumococcus, because
theoretically, VT would be eliminated with higher coverage before
observing the endemic steady state. The birth and death rate, m is
assumed to be m=1/70 per year for EV71 (crudely assuming an
industrialized country) and 1/54.2 per year for pneumococcus
(corresponding to the life expectancy at birth in Kenya [20]).
Results
Figure 2 examines the sensitivity of vaccine effectiveness using
the SIR model, while Figure 3 shows the effectiveness based on the
SIS model. For both models and vaccine types, both VER and
VEO were smaller than eVT, and VER yielded closer values to eVT
than VEO. Overall, the SIR model tended to be more sensitive to
vaccination coverage, the strength of naturally acquired cross-
protective immunity and vaccine efficacy against NVT than SIS
model does within the assumed parameter space. Regardless of the
types of vaccine, SIS model appeared to yield very consistent
estimates of vaccine effectiveness within the examined parameter
ranges.
Differential types of vaccine generated different patterns of
dependence on vaccination coverage, c and cross-protective
immunity, s. The larger c and s are for leaky type, the greater
the herd immunity and the higher both VER and VEO would be.
In contrast, all-or-nothing vaccine with large c and s decreases
VER and VEO. This is seen, because vaccinated individuals with
all-or-nothing type loose the chance of infection with both VT and
NVT, and as seen in equation (3), those naturally infected with
NVT would consequently be reduced, leading to reduced bA,AOR
and thus, decrease in VER and VEO.
We have also seen remarkable dependence of vaccine effective-
ness on the vaccine efficacy against NVT (Figures 2 and 3). The
difference between VEO and eVT is sensitive to vaccine efficacy
against NVT (eNVT), because VEO is a function of eNVT as we have
shown in equations (4) and (8). VEO would be lowered probably by
its involvement of eNVT in the denominator within the assumed
Figure 2. Vaccine effectiveness in the SIR (Susceptible-Infectious-Recovered) model. Field estimate (vertical axis) represents the vaccine
effectiveness estimate derived from empirical observation in the field. Solid line represents vaccine effectiveness based on odds ratio, VEO, while
broken line represents that based on relative risk, VER. Assumed vaccine efficacy against VT (vaccine type) is shown at the right end of each line.
Cross-protective immunity is expressed as perfect protection with a probability s for an all-or-nothing type vaccine, and expressed as the relative
reduction in the instantaneous risk of infection upon exposure against a serotype among those who have already experienced infection with the
other serotype for a leaky type vaccine. (a)-(c) show the effectiveness of all-or-nothing vaccine (i.e. perfect protection given successful immunization
and no protection for unsuccessful vaccination), whereas (d)-(f) show the effectiveness of leaky vaccine (i.e. imperfect protection for all vaccinated
individuals).
doi:10.1371/journal.pone.0050751.g002
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range. Assuming that the vaccine efficacy of all-or-nothing type
against VT are 70% (with the range from 60% to 80%) in the SIR
model with the baseline efficacy against NVT at 30%, VER and
VEO are estimated at 67.8% (range: 57.4% to 78.4%) and 57.4%
(43.5% to 71.3%), respectively. Employing the leaky type
assumption with the SIR model, VER and VEO are estimated at
53.1% (39.4% to 68.9%) and 49.0% (33.5% to 66.4%),
respectively. With all-or-nothing vaccine against VT with 82%
(with the range from 73% to 91%) in the SIS model along with the
baseline efficacy against NVT at 10%, VER and VEO are
estimated at 82.0% (73.0% to 91.0%) and 78.3% (67.0% to
89.1%), respectively. Employing leaky type assumption with SIS
model, VER and VEO are estimated at 80.7% (72.4% to 90.3%)
and 77.0% (67.1% to 88.5%), respectively.
For both models and both types of vaccine, higher assortativity
coefficients yield greater estimates of VER and VEO (Figure 4).
This is seen, because high assortative mixing strengthens herd
immunity among vaccinated individuals. That is, high assortativity
indicates that the vaccinated population is loosely connected with
the unvaccinated population, and thus, the herd immunity at the
subpopulation level tends to be elevated. Although equations (2)
and (3) imply that the estimate of VER is always smaller than eVT
in homogeneously mixing populations, Figure 4 indicates that the
impact of heterogeneous mixing (especially that influencing the
heterogeneity by vaccination status) on VER estimate is greater
than the underestimation factor seen in (2) and (3).
Discussion
The present study employed epidemiological models, investi-
gating how vaccine effectiveness is scaled by the vaccination
coverage and the two-strain transmission dynamics. Among all the
results, two findings are particularly notable. First, it appeared that
VER is closer to eVT than VEO, the gap of which appeared to
depend on vaccine efficacy against VT (eVT), vaccination
coverage, cross-protective immunity elicited by natural infection
and vaccine efficacy against NVT (eNVT). The difference between
VER and VEO estimates was more apparent in the SIR model
(EV71) than in the SIS model (pneumococcus). Second, among all
variables of interest, model structures and assumed vaccine types,
the vaccine efficacy against NVT, eNVT, appeared to have the
most profound impact on VEO, whereas VER was not sensitive to
eNVT. Both findings indicate that it is essential to understand the
transmission dynamics of non-vaccine types so that epidemiolog-
ical methods can appropriately measure the population impact of
vaccination [21].
Our study was originally motivated by the need to explicitly
assess the validity of indirect cohort method (Broome’s method) in
which the ‘‘odds ratio of vaccination’’ has been used for measuring
vaccine effectiveness, and thus, we expected this observation
method to be very sensitive to the dynamics of NVT. In the
present study, we have demonstrated that Broome’s method
remains quantitatively justified under particular scenarios, e.g.
especially when (i) vaccination does not protect infection with
NVT and (ii) VT and NVT are not interacting from each other.
Nevertheless, as can be clearly identified from the observation of
serotype replacement following the introduction of PCV7 [12], it is
evident that epidemiological interference exists between VT and
NVT for pneumococcus [22], and the reliance of Broome’s
method on NVT infections as controls has been known to be the
most important pitfall in appropriately assessing the vaccine
effectiveness. In the present study, we have additionally shown that
VEO is sensitive to vaccine efficacy against NVT. Thus, as the
most important caveat, we have demonstrated that the validity of
Broome’s method is highly dependent on the complex transmis-
sion dynamics including both naturally acquired immunity and
vaccine-induced immunity. Fortunately, both VER and VEO were
far less sensitive in the SIS model to other parameters than in the
SIR model, and thus, the use of Broome’s method in assessing the
effectiveness of pneumococcus vaccination may in part quantita-
tively be justified, which echoes with a suggestion in a published
study [11]. However, our exercise indicates that the validity of
effectiveness estimates based on indirect cohort method should be
subject to an explicit assessment by employing a prospective study
design (and thus, estimating VER), as long as the multi-strain
dynamics and the impact of vaccination on each strain have yet to
be fully quantified.
Given the potential limitation of the indirect cohort method
using presently available information, what are the data gap and
what one should plan to appropriately assess the vaccine
effectiveness? First, the most straightforward strategy to address
this issue may be to estimate VER based on a prospective study
design. Of course, the cohort study requires substantial time, effort
and cost, and moreover, the very low incidence of IPD is not
suitable outcome for this particular design [23], and thus, one may
have to consider measuring colonization rate by repeatedly
isolating S. pneumoniae from nasal and/or throat swabs over time
[24,25]. The other aspect that requires the serious attention in
future is to quantify the transmission dynamics of NVT, including
interactions between VT and NVT. In particular, whereas the
strength of cross-protective immunity between two different
serotypes has been statistically estimated [13], one can find very
few empirical estimate of the vaccine efficacy against NVT.
Moreover, the dynamics involving multiple antigenic types would
be more complex than we discussed here (unless symmetry in the
dynamics is considered). Third, it should be noted that our
discussions rest on an endemic equilibrium assumption. In reality,
the epidemiological observation takes place during non-linear
phase [26,27], and theoretical and epidemiological insights into
the vaccine effectiveness during such time period have yet to be
closely investigated.
As a supplementary analysis, we examined how the uncertainty
with respect to the model structure (i.e. SIS and SIR models)
relates to the validity of measuring VER and VEO. As a general
representation that can be interpreted as both SIS and SIR models
in special cases, we constructed and analyzed the so-called SIRS
(susceptible-infectious-recovered-susceptible) model with a decay
rate parameter d. If the rate of waning immunity d is zero, the
model is identical to SIR model, and as dR‘, the model is
interpreted as SIS model. In the online Supporting Information,
we have demonstrated that the expression of VER and VEO for
Figure 3. Vaccine effectiveness in the SIS (Susceptible-Infected-Susceptible) model. Field estimate (vertical axis) represents the vaccine
effectiveness estimate derived from empirical observation in the field. Solid line represents vaccine effectiveness based on odds ratio, VEO, while
broken line represents that based on relative risk, VER. Assumed vaccine efficacy against VT (vaccine type) is shown at the right end of each line.
Vaccine-induced immunity was dealt with as in two different ways, (i) all-or-nothing type or (ii) leaky type. (a)-(d) show the effectiveness of all-or-
nothing vaccine (i.e. perfect protection given successful immunization and no protection for unsuccessful vaccination), whereas (e)-(h) show the
effectiveness of leaky vaccine (i.e. imperfect protection for all vaccinated individuals).
doi:10.1371/journal.pone.0050751.g003
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SIRS model can be expressed as identical to what we have
examined for SIS and SIR models as shown above. Numerical
analysis of the SIRS model with varying d has shown that the
model structure has a little impact on VER and VEO (Figure S1),
and thus, our findings are regulated more strongly by other
parameters, notably including R0. In addition, we have shown that
indirect cohort method (i.e. the use of VEO) is sensitive to
asymmetric dynamics for VT and NVT, while VER appears to be
far less sensitive (Figure S2).
In summary, we have shown that the vaccine effectiveness VEO
calculated from odds ratio based on indirect cohort method can be
vulnerable to the model type (e.g. SIR or SIS), vaccine type (e.g.
all-or-nothing or leaky) and detailed mechanisms of interactions
between VT and NVT. As long as the multi-strain dynamics have
yet to be fully quantified, it is worthwhile to consider conducting
prospective studies to estimate the VER.
Supporting Information
Figure S1 Vaccine effectiveness in SIRS (Susceptible-
Infected-Recovered-Susceptible) model.
(TIF)
Figure S2 Vaccine effectiveness in SIS (Susceptible-
Infected- Susceptible) model.
(TIF)
Text S1 Supporting Information Text.
(DOC)
Figure 4. The relationship between vaccine effectiveness against VT (vaccine type) and assortativity coefficient h. Solid line represents
vaccine effectiveness based on odds ratio, VEO, while broken line represents that based on relative risk, VER. Vaccine efficacy against VT is shown at
the right end of lines. (a) and (c) show the result from SIR model, while (b) and (d) are from SIS model for Streptococcus pneumoniae. (a) and (b) show
the effectiveness of all-or-nothing vaccine (i.e. perfect protection given successful immunization and no protection for unsuccessful vaccination),
whereas (c) and (d) show the effectiveness of leaky vaccine (i.e. imperfect protection for all vaccinated individuals).
doi:10.1371/journal.pone.0050751.g004
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